Clavulanic acid ethers
    21.
    发明授权
    Clavulanic acid ethers 失效
    克拉维酸醚

    公开(公告)号:US4228174A

    公开(公告)日:1980-10-14

    申请号:US8421

    申请日:1979-02-01

    CPC分类号: C07D503/00

    摘要: The compounds of the formula (II): ##STR1## and salts and esters thereof wherein R is an inert organic group of up to 18 carbon atoms and are able to inhibit the action of various bacterial .beta.-lactamases. Thus when a compound of the formula (II) or its salt or ester is used together with a penicillin or cephalosporin, the effectiveness of that penicillin or cephalosporin can be considerably enhanced. These novel synergysts can be prepared by etherification of an ester of clavulanic acid followed if desired by de-esterification. The novel synergysts also possess antibacterial activity.

    摘要翻译: 式(II)的化合物:其中R是具有至多18个碳原子的惰性有机基团并能够抑制各种细菌β-内酰胺酶的作用的盐和酯。 因此,当将式(II)化合物或其盐或酯与青霉素或头孢菌素一起使用时,可以显着提高该青霉素或头孢菌素的有效性。 如果需要,通过脱酯化可以通过使克拉维酸的酯化来制备这些新颖的增效剂。 新型增效剂也具有抗菌活性。

    Antibiotic from Streptomyces clavulicerus
    24.
    发明授权
    Antibiotic from Streptomyces clavulicerus 失效
    来自链球菌的抗生素

    公开(公告)号:US4529720A

    公开(公告)日:1985-07-16

    申请号:US305337

    申请日:1981-09-24

    摘要: A new antibacterially active agent has been isolated from Streptomyces clavuligerus. This new compound which is designated clavulonic acid has the formula (I): ##STR1## In addition to being a broad spectrum antibiotic of medium potancy, clavulanic acid and its salts and esters have the ability to enhance the effectiveness of .beta. lactam antibiotics against many .beta.-lactamase producing bacteria.

    摘要翻译: 已经从Streptomyces clavuligerus中分离出一种新的抗菌活性剂。 这种被称为克拉维酸的新化合物具有式(I):除了广谱抗生素的中等耐药性之外,克拉维酸及其盐和酯具有增强β-内酰胺的有效性的能力 针对许多β-内酰胺酶生产细菌的抗生素。

    Antibacterial agents
    25.
    发明授权
    Antibacterial agents 失效
    抗菌剂

    公开(公告)号:US4428937A

    公开(公告)日:1984-01-31

    申请号:US216075

    申请日:1980-12-15

    申请人: Thomas T. Howarth

    发明人: Thomas T. Howarth

    摘要: The compounds of the formula: ##STR1## and salts and esters thereof are useful agents for the treatment of bacterial infections either alone or in combination with a penicillin or cephalosporin derivative. The preceding compounds may be prepared by the hydrogenation of a compound of the formula: ##STR2## wherein R is a hydrogen atom or an acyl group or a salt or ester thereof.

    摘要翻译: 下式的化合物及其盐和酯是单独或与青霉素或头孢菌素衍生物组合治疗细菌感染的有用试剂。 前述化合物可以通过下式化合物氢化制备:其中R是氢原子或酰基或其盐或酯。

    Azetidinoyl ethers
    26.
    发明授权
    Azetidinoyl ethers 失效
    氮杂环丁醚

    公开(公告)号:US4244965A

    公开(公告)日:1981-01-13

    申请号:US942348

    申请日:1978-09-14

    摘要: Compounds of the formula (I): ##STR1## and salts and esters thereof, wherein R.sub.1 is a hydrogen atom or a lower alkyl, aryl or aralkyl group, R.sub.2 and R.sub.3 are independently hydrogen, aryl, aralkyl, lower alkyl or substituted lower alkyl, or R.sub.3 is joined to R.sub.1 to form a 4-, 5-, or 6- membered ring or is joined to R.sub.2 to form a 5- or 6- membered ring with the proviso that when R.sub.2 is hydrogen, R.sub.1 is not hydrogen and R.sub.1 and R.sub.3 are not joined to form a group of the sub-formula (a) ##STR2## wherein R.sub.4 is a hydrogen atom or a NH.CO.R.sub.5 group wherein R.sub.5 is a lower alkyl, lower alkoxy lower alkyl, aryl, aralkyl, aryloxyalkyl, lower alkoxy or aryloxy group have .beta.-lactamase inhibitory and anti-bacterial properties.

    摘要翻译: 式(I)化合物:其中R 1为氢原子或低级烷基,芳基或芳烷基,R 2和R 3独立地为氢,芳基,芳烷基,低级烷基或 取代的低级烷基,或R 3与R 1连接形成4-,5-或6-元环,或连接至R 2以形成5-或6-元环,条件是当R 2为氢时,R 1为 不是氢并且R1和R3不连接形成一个子式(a)的基团,其中R4是氢原子或NH.CO.R5基团,其中R5是低级烷基,低级烷氧基低级烷基, 芳基,芳烷基,芳氧基烷基,低级烷氧基或芳氧基具有β-内酰胺酶抑制和抗菌性质。

    Clavulanic acid derivatives their preparation and use
    27.
    发明授权
    Clavulanic acid derivatives their preparation and use 失效
    克拉维酸衍生物的制备和用途

    公开(公告)号:US4215128A

    公开(公告)日:1980-07-29

    申请号:US942410

    申请日:1978-09-14

    申请人: Thomas T. Howarth

    发明人: Thomas T. Howarth

    摘要: This invention provides the compounds of the formula (II): ##STR1## and salts and esters thereof, wherein R.sub.1 is H and R.sub.3 is H or an aryl, aralkyl, lower alkyl or substituted lower alkyl group or R.sub.1 and R.sub.3 are joined so that the CHR.sub.1.NH.CO.R.sub.3 moiety forms a group of the sub-formula (a): ##STR2## wherein R.sub.4 is a hydrogen atom or a NH.CO.R.sub.5 group wherein R.sub.5 is a lower alkyl, lower alkoxy lower alkyl, aryl, aralkyl, aryloxyalkyl, lower alkoxy or aryloxy group.The compounds have .beta.-lactamase inhibitory and anti-bacterial properties.The invention also provides a process for their preparation, and pharmaceutical compositions containing them.

    摘要翻译: 本发明提供式(II)化合物:其中R 1为H且R 3为H或芳基,芳烷基,低级烷基或取代的低级烷基或R 1和R 3为 连接,使得CHR1.NH.CO.R3部分形成下式(a)的基团:其中R 4是氢原子或NH.CO.R 5基团,其中R 5是低级烷基,低级烷氧基 低级烷基,芳基,芳烷基,芳氧基烷基,低级烷氧基或芳氧基。 该化合物具有β-内酰胺酶抑制和抗细菌性质。 本发明还提供了其制备方法和含有它们的药物组合物。

    Oxoclavams
    30.
    发明授权

    公开(公告)号:US4088656A

    公开(公告)日:1978-05-09

    申请号:US745103

    申请日:1976-11-26

    CPC分类号: C07D503/00

    摘要: The compound of the formula (II): ##STR1## and its pharmaceutically acceptable salts and esters may be produced by ozonolysis of clavulanic acid and its derivatives. The compound has antibacterial and .beta.-lactamase inhibiting activity.

    摘要翻译: 式(II)化合物:其中药学上可接受的盐和酯可以通过克拉维酸及其衍生物的臭氧分解来制备。 该化合物具有抗菌和β-内酰胺酶抑制活性。